LG121071

LG121071
Clinical data
Other names	LG-121071; LGD-121071
Identifiers
	IUPAC name 6-Ethyl-4-(trifluoromethyl)-1H,2H,6H,7H,8H,9H-pyrido[3,2-g]quinolin-2-one;
CAS Number	179897-70-2 ;
PubChem CID	9839132;
ChemSpider	8014851;
UNII	242F29CP76;
ChEMBL	ChEMBL390728;
CompTox Dashboard (EPA)	DTXSID501045799 ;
Chemical and physical data
Formula	C15H15F3N2O
Molar mass	296.293 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1CCNC2=C1C=C3C(=CC(=O)NC3=C2)C(F)(F)F;
	InChI InChI=1S/C15H15F3N2O/c1-2-8-3-4-19-12-7-13-10(5-9(8)12)11(15(16,17)18)6-14(21)20-13/h5-8,19H,2-4H2,1H3,(H,20,21); Key:SZPPQFARTYXRKU-UHFFFAOYSA-N;

LG121071 (or LGD-121071) is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals that was first described in 1999 and was the first orally active nonsteroidal androgen to be discovered.^[1]^[2] It is a tricyclic quinolone derivative, structurally distinct from other nonsteroidal AR agonists like andarine and enobosarm (ostarine).^[2] The drug acts as a high-affinity full agonist of the androgen receptor (AR) (K_i = 17 nM),^[2] with a potency and efficacy that is said to be equivalent to that of dihydrotestosterone (DHT).^[3] Unlike testosterone, but similarly to DHT, LG121071 and other nonsteroidal androgens cannot be potentiated by 5α-reductase in androgenic tissues (nor aromatized into estrogenic metabolites), and for this reason, show tissue-selective androgenic effects.^[4] In accordance, they are said to possess full anabolic activity with reduced androgenic activity, similarly to anabolic-androgenic steroids.^[5]